ValiRx (VAL)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 5.77 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 1.47 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | -44.0% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, ValiRx Plc revenues decreased 52% to L216K. Net loss increased from L933K to L2.2M. Revenues reflect Drug Development segment decrease of 87% to L52K, UK segment decrease of 80% to L90K. Higher net loss reflects Research and development increase from L421K to L1M (expense), Administrative expenses increase of 36% to L1.5M (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 1 | 0 |
ValiRx Plc is an investment holding Company. The Company is engaged in developing technologies and products in oncology therapeutics and diagnostics. The Company operates in two segments: drug development and the sale of self-test drug kits. The Company is also engaged in developing a groundbreaking class of therapeutics based on the GeneICE platform and hypergenomics technology. The Company’s subsidiaries include ValiRx Bioinnovation Limited, which is the holding company, ValiPharma Limited, which is engaged in the therapeutic research and development; ValiMedix Limited, which is a medical diagnostics company and ValiRx Finland OY, which is engaged in therapeutic research and development. On August 18, 2011, the Company acquired ValiRx Finland OY. On January 5, 2012, the Company acquired Pharmatest Services Oy.
Directors: Nicholas Thorniley (Chmn.) , Satu Vainikka (CEO) 45, Gerald Desler (CFO) , George Morris (COO) , Kevin Alexander (Secy.) ,
No. of Employees: 9 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 1,711,184,409 |
| Free Float | 1.52bn (89.1%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | , LONDON, EC1N 8SS, United Kingdom |
| Web | http://www.valirx.com |
| Phone | +44 20 30084416 |
| Contact | K Alexander (Secy.) |
| Registrar | Capita Registrars (Kent) |
| Auditors | Adler Shine LLP |
| 13th Jun | Re: VAL201 Update |
| 6th Jun | ValiRx admitted as founder member of the SSE |
| 25th Apr | New Patent Granted |
| 22nd Apr | Result of AGM |
| 2nd Apr | Update on Developmental and Clinical Activity |
| 28th Mar | Final Results |
Recent ↓
